Search research articles
Contact Us
Filters
Showing results (111-120 of 714) with videos related to
Page
of 72
Sort By:
Pigment Cell & Melanoma Research
|
January 11, 2014
Cyclin-dependent kinases as therapeutic targets in melanoma
David M Miller, Keith T Flaherty
Journal of Travel Medicine
|
July 12, 2025
Tailored travel medicine: advancing personalised travel risk assessment through decision support tools
Luis Furuya-Kanamori, Gerard T Flaherty
Travel Medicine and Infectious Disease
|
January 22, 2025
Analysis of consular assistance provided to Irish citizens abroad, 2014-2023
Alan Alby, Aoife Power, Gerard T Flaherty
Future Oncology (London, England)
|
August 12, 2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment
Keiran S M Smalley, Keith T Flaherty
The American Journal of Tropical Medicine and Hygiene
|
July 27, 2022
Trend Analysis of Travel Medicine Topics Presented at an International Tropical Medicine Conference
Punyisa Asawapaithulsert, Gerard T Flaherty, Watcharapong Piyaphanee
Journal of Travel Medicine
|
April 11, 2023
Journal author funding sources and conflict of interest disclosures in travel medicine
Bryan W W Lim, Gerard T Flaherty
British Journal of Cancer
|
January 22, 2009
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
K S M Smalley, K T Flaherty
Cancer Biology & Therapy
|
February 1, 2007
Is ERK activation a good biomarker for estradiol and tamoxifen effects?
Keiran S M Smalley, Keith T Flaherty
Melanoma Management
|
September 8, 2018
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma
Philip Eliades, Keith T Flaherty, Hensin Tsao
Pigment Cell & Melanoma Research
|
July 22, 2009
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
Keith T Flaherty, Keiran S M Smalley
Page
of 72
Search research articles
Search
Showing results (111-120 of 714) with videos related to
Sort By:
Page
of 72
Pigment Cell & Melanoma Research
|
January 11, 2014
Cyclin-dependent kinases as therapeutic targets in melanoma
David M Miller, Keith T Flaherty
Journal of Travel Medicine
|
July 12, 2025
Tailored travel medicine: advancing personalised travel risk assessment through decision support tools
Luis Furuya-Kanamori, Gerard T Flaherty
Travel Medicine and Infectious Disease
|
January 22, 2025
Analysis of consular assistance provided to Irish citizens abroad, 2014-2023
Alan Alby, Aoife Power, Gerard T Flaherty
Future Oncology (London, England)
|
August 12, 2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment
Keiran S M Smalley, Keith T Flaherty
The American Journal of Tropical Medicine and Hygiene
|
July 27, 2022
Trend Analysis of Travel Medicine Topics Presented at an International Tropical Medicine Conference
Punyisa Asawapaithulsert, Gerard T Flaherty, Watcharapong Piyaphanee
Journal of Travel Medicine
|
April 11, 2023
Journal author funding sources and conflict of interest disclosures in travel medicine
Bryan W W Lim, Gerard T Flaherty
British Journal of Cancer
|
January 22, 2009
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
K S M Smalley, K T Flaherty
Cancer Biology & Therapy
|
February 1, 2007
Is ERK activation a good biomarker for estradiol and tamoxifen effects?
Keiran S M Smalley, Keith T Flaherty
Melanoma Management
|
September 8, 2018
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma
Philip Eliades, Keith T Flaherty, Hensin Tsao
Pigment Cell & Melanoma Research
|
July 22, 2009
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
Keith T Flaherty, Keiran S M Smalley
Page
of 72